JP2002544233A - 老人性痴呆症の治療に適した平均分子量が２，４００ｄに等しいグリコサミノグリカン - Google Patents

老人性痴呆症の治療に適した平均分子量が２，４００ｄに等しいグリコサミノグリカン

Info

Publication number
JP2002544233A
JP2002544233A JP2000617903A JP2000617903A JP2002544233A JP 2002544233 A JP2002544233 A JP 2002544233A JP 2000617903 A JP2000617903 A JP 2000617903A JP 2000617903 A JP2000617903 A JP 2000617903A JP 2002544233 A JP2002544233 A JP 2002544233A
Authority
JP
Japan
Prior art keywords
glycosaminoglycan
molecular weight
senile dementia
treatment
average molecular
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000617903A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002544233A5 (enExample
Inventor
コルネリ，ウンベルト
アンブロシ，ルイジ デ
ハニン，イスラエル
フェアエド，ジャウド
リー，ジョン
ロレンズ，スタンリー
メルヴィス，ロナルド，エフ．
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2002544233A publication Critical patent/JP2002544233A/ja
Publication of JP2002544233A5 publication Critical patent/JP2002544233A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
    • C08B37/0078—Degradation products

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Polymers & Plastics (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
  • Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
  • Treatments Of Macromolecular Shaped Articles (AREA)
JP2000617903A 1999-05-14 2000-05-12 老人性痴呆症の治療に適した平均分子量が２，４００ｄに等しいグリコサミノグリカン Pending JP2002544233A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT99A001066 1999-05-14
IT1999MI001066A IT1312107B1 (it) 1999-05-14 1999-05-14 Glicosaminoglicani aventi peso molecolare medio di 2400 d atti altrattamento della demenza senile
PCT/EP2000/004311 WO2000069444A1 (en) 1999-05-14 2000-05-12 Glycosaminoglycans having an average molecular weight equal to 2400 d suitable for the treatment of senile dementia

Publications (2)

Publication Number Publication Date
JP2002544233A true JP2002544233A (ja) 2002-12-24
JP2002544233A5 JP2002544233A5 (enExample) 2007-07-12

Family

ID=11382970

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000617903A Pending JP2002544233A (ja) 1999-05-14 2000-05-12 老人性痴呆症の治療に適した平均分子量が２，４００ｄに等しいグリコサミノグリカン

Country Status (22)

Country Link
US (1) US6979680B1 (enExample)
EP (1) EP1181024B1 (enExample)
JP (1) JP2002544233A (enExample)
KR (1) KR100711142B1 (enExample)
CN (1) CN1178667C (enExample)
AT (1) ATE288761T1 (enExample)
AU (1) AU764743C (enExample)
CA (1) CA2373975A1 (enExample)
CZ (1) CZ20014092A3 (enExample)
DE (1) DE60018061T2 (enExample)
DK (1) DK1181024T3 (enExample)
ES (1) ES2237425T3 (enExample)
HK (1) HK1039903B (enExample)
HU (1) HUP0201100A3 (enExample)
IL (1) IL146458A0 (enExample)
IT (1) IT1312107B1 (enExample)
NO (1) NO328902B1 (enExample)
PL (1) PL198016B1 (enExample)
PT (1) PT1181024E (enExample)
RU (1) RU2248800C2 (enExample)
WO (1) WO2000069444A1 (enExample)
ZA (1) ZA200109331B (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006528670A (ja) * 2003-05-21 2006-12-21 コルネッリ・ウンベルト 情緒障害処置用グリコサミノグリカン
JP2015502332A (ja) * 2011-10-14 2015-01-22 サントル ナショナル ドゥ ラ ルシェルシュ シアンティフィク 神経変性疾患の診断、予後予測又は治療の方法

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1344781A1 (en) * 2002-03-12 2003-09-17 Laboratori Derivati Organici S.P.A. Process for the depolymerization of glycosaminoglycanes and products obtained therefrom
EP1524276A1 (en) * 2003-10-16 2005-04-20 Laboratori Derivati Organici S.P.A. Multistep process for the physical depolymerization of heparin and products obtained therefrom
US7939512B2 (en) 2004-10-13 2011-05-10 Laboratori Derivati Organici Spa Multistep process for the physical depolymerization of heparin and products obtained therefrom
DE602006016990D1 (de) 2005-12-22 2010-10-28 Bellus Health Int Ltd Behandlung von diabetischer nephropathie
WO2009007224A1 (en) * 2007-07-10 2009-01-15 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Low molecular weight heparin derivatives having neuroprotective activity
US8896239B2 (en) 2008-05-22 2014-11-25 Vladimir Yegorovich Balakin Charged particle beam injection method and apparatus used in conjunction with a charged particle cancer therapy system
CN102119586B (zh) 2008-05-22 2015-09-02 弗拉迪米尔·叶戈罗维奇·巴拉金 多场带电粒子癌症治疗方法和装置
JP5450602B2 (ja) 2008-05-22 2014-03-26 エゴロヴィチ バラキン、ウラジミール シンクロトロンによって加速された荷電粒子を用いて腫瘍を治療する腫瘍治療装置
EP2283713B1 (en) 2008-05-22 2018-03-28 Vladimir Yegorovich Balakin Multi-axis charged particle cancer therapy apparatus
US8841866B2 (en) 2008-05-22 2014-09-23 Vladimir Yegorovich Balakin Charged particle beam extraction method and apparatus used in conjunction with a charged particle cancer therapy system
SG173879A1 (en) 2009-03-04 2011-10-28 Protom Aozt Multi-field charged particle cancer therapy method and apparatus
US8609097B2 (en) * 2009-06-10 2013-12-17 Hoffmann-La Roche Inc. Use of an anti-Tau pS422 antibody for the treatment of brain diseases
CN112426434A (zh) * 2020-11-04 2021-03-02 山东大学 硫酸乙酰肝素在防治阿尔兹海默症中的应用
CN114478816A (zh) * 2022-02-11 2022-05-13 上海兴糖生物技术有限公司 一种白玉蜗牛多糖及其制备方法和用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63213502A (ja) * 1986-11-24 1988-09-06 ラボラトーリ・デリヴァーティ・オルガニチ・エス．ピー．エイ． 低分子量グルコサミノグルカンの制御製造方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4351938A (en) * 1980-05-19 1982-09-28 Riker Laboratories, Inc. Anticoagulant substance
US4847338A (en) * 1985-03-28 1989-07-11 University Of Iowa Research Foundation Low molecular weight heparin fragments as inhibitors of complement activation
EP0243974B1 (en) * 1986-05-01 1994-03-02 Toppan Printing Co., Ltd. Scanner set-up simulation apparatus
IT1205042B (it) * 1987-05-28 1989-03-10 Crinos Industria Farmaco Composizione farmaceutica ad attivita' terapeutica per il trattamento della demenza senile di tipo alzheimer
EP0337327A1 (en) * 1988-04-09 1989-10-18 Bioiberica, S.A. Process for the preparation of new oligosaccharide fractions by controlled chemical depolimerization of heparin
IT1240615B (it) * 1990-04-03 1993-12-17 Mediolanum Farmaceutici Spa Impiego del dermatan solfato nella prevenzione e terapia dell'invecchiamento cerebrale e degli stati di deficit funzionale del sistema nervoso centrale
IL100555A (en) * 1991-02-07 2000-08-31 Hoechst Marion Roussel Inc N-substituted quinoline derivatives their preparation their use for the preparation of medicaments and the pharmaceutical compositions containing them
SK279285B6 (sk) * 1991-05-02 1998-09-09 Daiichi Pharmaceutical Co. Použitie n-(2,6-dimetylfenyl)-2-(2-oxo-1-pyrolidin
RU2106864C1 (ru) * 1995-10-23 1998-03-20 Николай Серафимович Зефиров Средство для лечения болезни альцгеймера

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63213502A (ja) * 1986-11-24 1988-09-06 ラボラトーリ・デリヴァーティ・オルガニチ・エス．ピー．エイ． 低分子量グルコサミノグルカンの制御製造方法

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006528670A (ja) * 2003-05-21 2006-12-21 コルネッリ・ウンベルト 情緒障害処置用グリコサミノグリカン
JP4757197B2 (ja) * 2003-05-21 2011-08-24 コルネッリ・ウンベルト 情緒障害処置用グリコサミノグリカン
JP2015502332A (ja) * 2011-10-14 2015-01-22 サントル ナショナル ドゥ ラ ルシェルシュ シアンティフィク 神経変性疾患の診断、予後予測又は治療の方法

Also Published As

Publication number Publication date
NO328902B1 (no) 2010-06-14
DE60018061D1 (de) 2005-03-17
EP1181024A1 (en) 2002-02-27
NO20015544D0 (no) 2001-11-13
CN1178667C (zh) 2004-12-08
HK1039903A1 (en) 2002-05-17
AU4405200A (en) 2000-12-05
HK1039903B (en) 2005-08-26
HUP0201100A2 (hu) 2002-07-29
AU764743B2 (en) 2003-08-28
AU764743C (en) 2004-03-18
CZ20014092A3 (cs) 2002-04-17
PL352070A1 (en) 2003-07-28
PT1181024E (pt) 2005-06-30
CA2373975A1 (en) 2000-11-23
IT1312107B1 (it) 2002-04-04
ATE288761T1 (de) 2005-02-15
ES2237425T3 (es) 2005-08-01
HUP0201100A3 (en) 2003-03-28
PL198016B1 (pl) 2008-05-30
NO20015544L (no) 2002-01-14
US6979680B1 (en) 2005-12-27
EP1181024B1 (en) 2005-02-09
DK1181024T3 (da) 2005-06-13
CN1350459A (zh) 2002-05-22
DE60018061T2 (de) 2006-04-13
ITMI991066A1 (it) 2000-11-14
KR100711142B1 (ko) 2007-04-24
KR20020005033A (ko) 2002-01-16
ZA200109331B (en) 2002-08-28
RU2248800C2 (ru) 2005-03-27
IL146458A0 (en) 2002-07-25
WO2000069444A1 (en) 2000-11-23

Similar Documents

Publication Publication Date Title
JP2002544233A (ja) 老人性痴呆症の治療に適した平均分子量が２，４００ｄに等しいグリコサミノグリカン
Plant et al. Inhibitory proteoglycan immunoreactivity is higher at the caudal than the rostral Schwann cell graft-transected spinal cord interface
CA2547531C (en) Buoyant polymer particles for delivery of therapeutic agents to the central nervous system
DE69633336T2 (de) Zusamenzetzung enthaltend einen inhibitor des myelin assoziierten glycoproteins (mag), welcher einer veränderten oder mutierten form von mag enthält
JP3264560B2 (ja) 急性末梢神経障害治療用組成物
DE3422518A1 (de) Heparin-derivate, verfahren zu ihrer herstellung, diese enthaltende arzneimittel und ihre verwendung bei der behandlung von fettstoffwechselstoerungen
US6573251B2 (en) Drug and pharmaceutical composition for the treatment of lesions of the nervous system and fractions enriched in heparan sulfate
Walzer et al. Low molecular weight glycosaminoglycan blockade of β-amyloid induced neuropathology
Thanos et al. Traumatology of the optic nerve and contribution of crystallins to axonal regeneration
David et al. Book Review: Recruiting the Immune Response to Promote Axon Regeneration in the Injured Spinal Cord
JPH10503472A (ja) 筋肉処置のためのバイオポリマーの使用
DE69121058T2 (de) Salze von Glykosaminoglykanen mit Aminosäureester, ihre Herstellung sowie sie enthaltende pharmazeutische Zusammensetzungen
JPH10503168A (ja) 神経系の損傷の処置のための置換デキストランの使用ならびにヘパラン硫酸に富む分画
CN1223351C (zh) 低分子量肝素在制备预防和治疗脑水肿药物中的应用
TW200922605A (en) Composition and treatment
DE69113437T2 (de) Therapeutische Mittel für diabetisches Gangrän.
EP4048257A1 (en) Treatment of conditions of the nervous system
CA2064787A1 (en) Dopaminergic neurotrophic factor for treatment of parkinson's disease
Liu et al. Motoneurotrophins derived from limb buds protect the motoneurons in anterior spinal cord after nerve injury and promote nerve regeneration
Dudas et al. Low molecular weight glycosaminoglycan C3 attenuates AF64A-stimulated, low-affinity nerve growth factor receptor-immunoreactive axonal varicosities in the rat septum
US20160361255A1 (en) Peptide Nanotubes for Slow Release of Drugs at Peripheral Nerve Injury
EA046226B1 (ru) Применение фармацевтической композиции в качестве лекарственного средства для защиты и/или репарации/восстановления гематоэнцефалического барьера
DE102004057196A1 (de) Verfahren zur Herstellung von Albumin-Konjugaten mit Nicht-steroidalen Antirheumatika (NSAR)
JPH04173744A (ja) 神経細胞保護剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070511

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070511

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100921

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110308